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This article will examine issues in the use of epidemiologic and other types of data in dietary reference intake development,
and offer an approach toward integration.
In1994, the framework to determine revised dietary reference intakes (DRIs) was meant to incorporate the concept of risk
reduction of chronic disease (Institute of Medicine, 1994). However, of the 19 estimated average requirements (EARs) that were
established, none were able to be set on the basis of a chronic disease end point because of inadequacies in the available data.
Adequate intake levels were partially determined by using disease end points for ﬁve nutrients: calcium (fracture rates), vitamin
D (fracture rates), ﬂuoride (dental carries), potassium (hypertension, kidney stones), and ﬁber (coronary heart disease).
Using chronic disease end points was found to be difﬁcult for setting individual nutrient DRIs for a number of reasons:
1. Chronic diseases have long latencies in their development, which results in almost inevitable inconsistencies in the data and
makes them difﬁcult and expensive to study.
2. Chronic diseases have numerous linkages to genetic and environmental factors. Risk of a chronic disease can never be brought
to zero or reach 100% by any single nutritional intervention (Trumbo, 2008). The notion of attributable risk assumes that each
factor is independent of every other factor, which is almost certainly not true.
3. Foods are complex entities. Attributing a chronic disease (e.g., cancer) linkage of a food (e.g., vegetables) to a speciﬁc nutrient
(e.g., carotene) contained in that food is fraught with uncertainty.
4. Many studies on nutrients and chronic disease prevention were conducted as secondary prevention studies, rather than primary
prevention studies. Extrapolation of the results of a secondary prevention study to primary prevention of a disease cannot be
done and the results cannot, therefore, be translated into a public health recommendation.
5. Intervention studies on nutrients and chronic disease prevention have generally used single nutrients or a small number of
combined nutrients. Such studies are expensive to conduct, and few have incorporated dose responses, which are a necessary
component in DRI development.
Because of the nature of the enumerated issues above, it can be concluded that prospective cohort studies can and do play a key
and important role in initial hypothesis formation (as well as a conﬁrmatory role) of chronic disease-nutrient linkages. However,
such studies alone cannot yield deﬁnitive answers because of the uncertainties already mentioned that arise from long-term latency
periods and from the multiple etiologic causative or modifying factors in chronic disease development. Results from prospective
cohort studies (and, less importantly, observational epidemiologic studies) must be combined with evidence from experimental,
animal, and small-scale, randomized, controlled clinical studies, which have used veriﬁed biomarkers of effect (i.e., biomarkers
in the pathway of, or predictive of, chronic disease development) as end points (Institute of Medicine, 2008). Such biomarkers as
effectors or predictors of chronic disease would have previously been demonstrated in prospective cohort and clinical intervention
studies.
Veriﬁed biomarkers of effect require an understanding of metabolic trafﬁcking and can be enormously useful for decreasing
the cost of studies, for providing early answers, and for studying dose-response relationships. In addition, such biomarkers should
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be safe to use in large-scale studies and in public health interventions. The interplay between the various types of studies will be
an essential part of future DRI development.
Thus, the results from several different types of studies (experimental, epidemiologic, and clinical) should be moving in the
samedirectionwithconsistency,tobeusefulfordeterminingDRIsforindividualnutrients.Inmostcases,itwouldnotbenecessary
to perform large-scale, randomized, and controlled nutrient-intervention trials. This gold standard type of study should be applied
very selectively and only for questions of extreme public health relevance, and after a synthesis of data from all of the other various
types of studies has been performed. Systematic reviews, to include meta-analysis, should always be used to complete such a
synthesis (Lichtenstein et al., 2008), both in the process of designing costly intervention trials and during the DRI development
process itself.
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